Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

US11912711B2 · kind B2 · utility

Assignees

• AMGEN INC. · US
• VIGIL NEUROSCIENCE, INC. · US

Inventors

• Lara C. Czabaniuk · Thousand Oaks, US
• Timothy Hopper · Thousand Oaks, US
• Jonathan Houze · Cambridge, US
• Jane Panteleev · Boston, US
• Gwenaella Rescourio · Thousand Oaks, US
• Vincent Santora · Thousand Oaks, US
• Haoxuan Wang · Thousand Oaks, US
• Ryan White · Thousand Oaks, US
• Alice R. Wong · Thousand Oaks, US
• Yongwei Wu · Longbeilingcun, CN
• Maxence Bos · Saint-Laurent, CA
• John Mancuso · Vaudreuil-Dorion, CA
• Ivan FRANZONI · Saint-Laurent, CA

Key dates

• Filing date: Nov 30, 2022
• Grant date: Feb 27, 2024
• Expiry date: Jan 9, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D475/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.